Insights

Same Molecule, Same Rights? The Rifaximin Lesson in Solid-State Strategy

Rifaximin's polymorph dispute shows that chemical identity alone does not guarantee commercial or regulatory equivalence.

1 November 2026 6 min read PCL Research & Manufacturing
Same Molecule, Same Rights? The Rifaximin Lesson in Solid-State Strategy

Development teams routinely assume that matching an API’s molecular structure is enough to secure freedom to operate and a clean regulatory path. The rifaximin polymorph dispute, one of the most closely watched solid-state patent cases in recent memory, showed how costly that assumption can be.

The Assumption Behind a Costly Surprise

Most CMC and business development teams work from a simple mental model: same active pharmaceutical ingredient, same CAS number, same INN, therefore broadly comparable regulatory and IP exposure. Under this logic, replicating an approved molecule is treated primarily as a synthesis and formulation problem, with patent risk concentrated around the core molecule patent and its expiry date.

That model is incomplete, and the gap it leaves is exactly where solid-state chemistry lives. A molecule can exist in multiple crystalline arrangements, each with distinct solubility, dissolution behavior, stability, and manufacturability. Those differences are not cosmetic. They can be, and often are, independently patented, creating an IP layer that has nothing to do with the molecule’s basic composition claim.

What Happened With Rifaximin

Rifaximin, a non-systemic antibiotic used in gastrointestinal indications, is a textbook example of a drug substance with a documented polymorph landscape: multiple crystalline forms with different physicochemical behavior, some of which were claimed in separate patents tied to specific manufacturing and formulation strategies rather than to the molecule itself.

When generic developers set out to bring rifaximin to market, replicating the active ingredient was only the starting point. The commercially relevant crystalline form, and the patents protecting it, became central to a protracted and closely watched dispute in the US generics landscape, with outcomes that shaped how later entrants approached the molecule.

The details of any single litigation are case-specific and evolve with court rulings, so we treat rifaximin here as an illustration of a structural issue rather than as a template for predicting outcomes in other programs. The structural issue is this: the molecule and its solid form can carry entirely separate legal lives.

Our Position: Crystal Form Is a Distinct Asset, Not a Technicality

We take a clear position on this, informed by years of polymorph screening, co-crystal discovery, and solid-state characterization work: crystal form is a distinct, independently valuable asset. It is not a downstream technicality that can be resolved once the chemistry and the regulatory filing are otherwise finished.

Solid form determines dissolution rate, which determines bioavailability, which determines whether a formulation can meet bioequivalence requirements at all. It determines physical and chemical stability under real-world storage and shipping conditions. It determines whether a process is scalable and reproducible at manufacturing volumes. And, as rifaximin demonstrated, it can determine whether a product can be sold at all, independent of the status of the base molecule patent.

Treating solid form selection as an afterthought, or assuming that any thermodynamically convenient crystal will do, ignores a layer of technical and legal risk that competitors and litigators understand very well. The companies that win in this space are the ones that understand their own polymorph landscape, and their competitors’, before they commit capital to scale-up.

The Counter-Argument We Take Seriously

The strongest objection to this position is a fair one, and we do not dismiss it. Critics, including many voices in the generics industry and in access-to-medicines advocacy, argue that polymorph patents are frequently used for evergreening: extending commercial exclusivity well beyond the life of the original molecule patent without delivering meaningful therapeutic innovation.

There is real substance to this critique. Not every polymorph patent reflects genuine, non-obvious inventive step, and courts in multiple jurisdictions have invalidated weak solid-form claims on exactly those grounds. A policy environment that makes it too easy to extend exclusivity through incremental crystal-form claims is not healthy for competition or for patient access.

Why the Counter-Argument Doesn’t Change the Operating Reality

Here is where we draw the line. The evergreening debate is a legitimate policy question, and it will continue to be litigated, legislated, and argued in professional journals. But it does not change the operating reality facing a company planning a development program today.

Polymorph patents, whether or not one thinks they should be grantable in principle, are being filed, granted, and enforced right now, in every major market. Courts evaluate them case by case, on their specific claims and prior art, not on the general merits of the evergreening debate. A development team that waits for policy reform, or that assumes a court will eventually see things their way, is making a bet with someone else’s timeline and someone else’s capital.

De-risking, in our view, means operating as the regulatory and IP environment actually is, not as one might wish it to be. That means mapping the solid-form landscape of a target molecule early, understanding which forms are claimed and by whom, and building a development strategy that accounts for that reality before manufacturing investment is committed, not after a cease-and-desist letter arrives.

What Rigorous Solid-Form Strategy Looks Like

In practice, this means treating solid-state screening as a strategic activity with its own budget, timeline, and decision gates, rather than a routine QC step inserted late in development. A thorough program typically includes:

The CMC and Regulatory Dimension Beyond IP

The rifaximin case is often discussed purely as a patent story, but the underlying lesson is broader than litigation risk. Solid form selection feeds directly into the CMC package: it shapes the stability data a company will need to generate, the specifications it will need to defend to regulators, and the manufacturing process it will need to validate at scale.

A molecule that performs well analytically in one crystalline form but poorly in another can create bioequivalence problems, stability failures under ICH storage conditions, or manufacturability issues that only surface during scale-up. These are precisely the kinds of late-stage surprises that an integrated, data-driven approach to solid-state development is designed to catch early, when changing course is still inexpensive.

This is the thinking behind PCL Research & Manufacturing’s approach to solid form development: polymorph screening, co-crystal and salt selection, and stability screening are treated as interconnected disciplines that inform both the regulatory strategy and the commercial manufacturing plan from the outset, rather than as isolated laboratory exercises performed in sequence.

Rifaximin is not an isolated curiosity. It is a clear illustration of a pattern that recurs across small-molecule development whenever a valuable product reaches the point where others want to replicate it: the molecule gets the headline, but the crystal form often decides the outcome. If your team is mapping a solid-form strategy, evaluating freedom to operate on a target molecule, or trying to understand what a polymorph landscape actually looks like before committing to scale-up, we would welcome a conversation.

Share

More insights

All articles